Michael J. Blaha, MD, MPH

Director of Clinical Research Ciccarone Center for the Prevention of Heart Disease

Michael J. Blaha, MD, MPH

Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Associate Professor of Medicine
Johns Hopkins School of Medicine
Baltimore, MD

Related Videos

What should the “threshold” of 70 mg/dL identified in the AHA Guidelines mean to the medical or preventive cardiologist in his/her aspiration to optimize CV risk reduction in high-risk patients with a history of ACS or related high-risk features? Video

What should the “threshold” of 70 mg/dL identified in the AHA Guidelines mean to the medical or preventive cardiologist in his/her aspiration to optimize CV risk reduction in high-risk patients with a history of ACS or related high-risk features?

How do you approach younger patients with known, advanced subclinical atherosclerosis? Video

How do you approach younger patients with known, advanced subclinical atherosclerosis?

Which patients, in your view, based on the ODYSSEY Outcomes and FOURIER trials, do you want to drive below the LDL-C “threshold” of 70 mg/dL? What is your rationale and how do you select your patients and achieve your targets in the real world? Video

Which patients, in your view, based on the ODYSSEY Outcomes and FOURIER trials, do you want to drive below the LDL-C “threshold” of 70 mg/dL? What is your rationale and how do you select your patients and achieve your targets in the real world?

Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction? Video

Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?